Johnson & Johnson
Price: 238.49Company and Business Model
Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.
Investment Profile
Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.
Fundamental metrics (experimental)
- EPS (TTM) — earnings per share for the last 12 months, $
- 8.67 OK
- Revenue QoQ — quarter-over-quarter revenue growth
- -2.0% ↓
- EPS surprise
- 0.7% in line
- 20d volatility
- 1.3% stable
- Dividend yield
- 2.3% moderate last ex-date: 2026-05-26
Forecast impact
positiveTrack in portfolio
Price chart
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-10 00:46 | Hold | Buy | Strong momentum and solid dividend yield support growth. |
| 2026-05-30 02:42 | Buy | Hold | Weak momentum and fundamentals raise uncertainty. |
| 2026-05-22 02:50 | Hold | Buy | Stable dividends, but mixed momentum signals present uncertainty. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-13 10:04 | Leerink Partners | Rating Upgraded | — → 265 | 224.26 |
| 2026-04-20 12:24 | Guggenheim | Target Raised | 244 → 266 | 232.71 |
| 2026-04-15 12:31 | Morgan Stanley | Target Raised | 267 → 283 | 239.66 |